title: Pay-for-performance pricing for a breakthrough heart drug: learnings for cell and gene therapies.
authors.affiliation: Asklepian Consulting, International House, 24 Holborn Viaduct, London, EC1A 2BN, UK.
authors.forename: Nafees N
authors.initials: NN
authors.lastname: Malik
mesh_terms: D000613:Aminobutyrates / Q000191:economics*; D001713:Biphenyl Compounds; D064987:Cell- and Tissue-Based Therapy / Q000191:economics / Q000379:methods; D004338:Drug Combinations; D005060:Europe; D015316:Genetic Therapy / Q000191:economics / Q000379:methods; D005102:Health Expenditures; D006801:Humans; D013777:Tetrazoles / Q000191:economics*; D014481:United States; D000068756:Valsartan
chemical_list: D000613:Aminobutyrates; D001713:Biphenyl Compounds; D004338:Drug Combinations; D013777:Tetrazoles; D000068756:Valsartan; C549068:sacubitril and valsartan sodium hydrate drug combination
keywords: commercialization; health economics; market access; outcomes; pay-for-performance; payer; pricing; reimbursement; risk-sharing